137 related articles for article (PubMed ID: 38548416)
1. Humanized mouse models for anti-cancer therapy.
Baietti MF; Leucci E
Methods Cell Biol; 2024; 183():317-333. PubMed ID: 38548416
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
4. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
Verma B; Wesa A
Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
[TBL] [Abstract][Full Text] [Related]
5. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
Okada S; Vaeteewoottacharn K; Kariya R
Cells; 2019 Aug; 8(8):. PubMed ID: 31412684
[TBL] [Abstract][Full Text] [Related]
6. Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.
Yan C; Nebhan CA; Saleh N; Shattuck-Brandt R; Chen SC; Ayers GD; Weiss V; Richmond A; Vilgelm AE
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509357
[TBL] [Abstract][Full Text] [Related]
7. A Humanized Patient-Derived Xenograft Model for Pancreatic Cancer.
Lundy J
Methods Mol Biol; 2024; 2806():91-100. PubMed ID: 38676798
[TBL] [Abstract][Full Text] [Related]
8. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
9. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenograft models in cancer therapy: technologies and applications.
Liu Y; Wu W; Cai C; Zhang H; Shen H; Han Y
Signal Transduct Target Ther; 2023 Apr; 8(1):160. PubMed ID: 37045827
[TBL] [Abstract][Full Text] [Related]
11. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
12. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenograft (PDX) models, applications and challenges in cancer research.
Abdolahi S; Ghazvinian Z; Muhammadnejad S; Saleh M; Asadzadeh Aghdaei H; Baghaei K
J Transl Med; 2022 May; 20(1):206. PubMed ID: 35538576
[TBL] [Abstract][Full Text] [Related]
14. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors.
Bondarenko G; Ugolkov A; Rohan S; Kulesza P; Dubrovskyi O; Gursel D; Mathews J; O'Halloran TV; Wei JJ; Mazar AP
Neoplasia; 2015 Sep; 17(9):735-741. PubMed ID: 26476081
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor.
Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P
Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347
[TBL] [Abstract][Full Text] [Related]
17. Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy.
Wu C; Wang X; Shang H; Wei H
Dis Markers; 2022; 2022():1479246. PubMed ID: 36072895
[TBL] [Abstract][Full Text] [Related]
18. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J
Front Immunol; 2021; 12():607282. PubMed ID: 33854497
[TBL] [Abstract][Full Text] [Related]
19. Towards precision oncology with patient-derived xenografts.
Zanella ER; Grassi E; Trusolino L
Nat Rev Clin Oncol; 2022 Nov; 19(11):719-732. PubMed ID: 36151307
[TBL] [Abstract][Full Text] [Related]
20. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
Meehan TF; Conte N; Goldstein T; Inghirami G; Murakami MA; Brabetz S; Gu Z; Wiser JA; Dunn P; Begley DA; Krupke DM; Bertotti A; Bruna A; Brush MH; Byrne AT; Caldas C; Christie AL; Clark DA; Dowst H; Dry JR; Doroshow JH; Duchamp O; Evrard YA; Ferretti S; Frese KK; Goodwin NC; Greenawalt D; Haendel MA; Hermans E; Houghton PJ; Jonkers J; Kemper K; Khor TO; Lewis MT; Lloyd KCK; Mason J; Medico E; Neuhauser SB; Olson JM; Peeper DS; Rueda OM; Seong JK; Trusolino L; Vinolo E; Wechsler-Reya RJ; Weinstock DM; Welm A; Weroha SJ; Amant F; Pfister SM; Kool M; Parkinson H; Butte AJ; Bult CJ
Cancer Res; 2017 Nov; 77(21):e62-e66. PubMed ID: 29092942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
